Intensification of glucose-lowering treatment in patients with diabetes mellitus type 2 on insulin therapy: Perspectives of dapagliflozin

被引：0
|
作者：
Sukhareva, O. Y. [1 ]
Shestakova, M., V [1 ,2 ]
机构：
[1] Endocrinol Res Ctr, Moscow, Russia
[2] Sechenov First Moscow State Med Univ, Moscow, Russia
来源：
DIABETES MELLITUS | 2016年 / 19卷 / 01期
关键词：
diabetes mellitus type 2; insulin therapy; SGLT-2; inhibitor; dapagliflozin;
D O I：
10.14341/DM7745
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Intensification of antihyperglycaemic treatment in patients with poorly controlled type 2 diabetes mellitus who were on insulin therapy remains a difficult issue. Results from clinical trials with the sodium-glucose linked transporter (SGLT-2) inhibitor dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus using insulin are summarised and discussed in the article.
引用
收藏
页码：72 / 79
页数：8
相关论文
共 50 条
  • [1] Initiation of glucose-lowering therapy in Type 2 diabetes mellitus patients in general practice
    Spoelstra, JA
    Stolk, RP
    Klungel, OH
    Erkens, JA
    Rutten, GEHM
    Leufkens, HGM
    Grobbee, DE
    [J]. DIABETIC MEDICINE, 2004, 21 (08) : 896 - 900
  • [2] Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus
    Jung-Im Shin
    [J]. Current Diabetes Reports, 2019, 19
  • [3] Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus
    Shin, Jung-Im
    [J]. CURRENT DIABETES REPORTS, 2019, 19 (08)
  • [4] Intensification of polypharmacy glucose-lowering treatment in type-2 diabetes: When to be cautious?
    Charbonnel, Bernard
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2012, 97 (01) : 3 - 5
  • [5] Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study
    Bongaerts, Brenda
    Arnold, Suzanne, V
    Charbonnel, Bernard H.
    Chen, Hungta
    Cooper, Andrew
    Fenici, Peter
    Gomes, Marilia
    Ji, Linong
    Khunti, Kamlesh
    Kosiborod, Mikhail
    Medina, Jesus
    Nicolucci, Antonio
    Shestakova, Marina
    Shimomura, Iichiro
    Tang, Fengming
    Watada, Hirotaka
    Rathmann, Wolfgang
    [J]. BMJ OPEN DIABETES RESEARCH & CARE, 2021, 9 (01)
  • [6] Impact of early or late intensification of glucose-lowering therapy in patients with type 2 diabetes: the global DISCOVER study
    Ramirez, L.
    Ji, L.
    Bonnet, F.
    Chen, H.
    Cooper, A.
    Hammar, N.
    Leigh, P.
    Saraiva, G. L.
    Medina, J.
    Nicolucci, A.
    Rathmann, W.
    Shestakova, M. V.
    Surmont, F.
    Tang, F.
    Watada, H.
    [J]. DIABETOLOGIA, 2020, 63 (SUPPL 1) : S148 - S149
  • [7] Glucose-lowering therapy and cardiovascular outcomes in patients with type 2 diabetes mellitus and acute coronary syndrome
    Avogaro, Angelo
    Bonora, Enzo
    Consoli, Agostino
    Del Prato, Stefano
    Genovese, Stefano
    Giorgino, Francesco
    [J]. DIABETES & VASCULAR DISEASE RESEARCH, 2019, 16 (05): : 399 - 414
  • [8] Is It Enough Glucose-Lowering Therapy for Men with Type 2 Diabetes Mellitus and Testosterone Deficiency?
    Khripun, Irina A.
    Bova, Elena V.
    Vorobyev, Sergey V.
    Dzantieva, Elizaveta O.
    Belousov, Igor I.
    Kogan, Michail I.
    [J]. DIABETES, 2017, 66 : A399 - A399
  • [9] Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus
    Hector E. Tamez
    Alejandra L. Tamez
    Lucas A. Garza
    Mayra I. Hernandez
    Ana C. Polanco
    [J]. Journal of Diabetes & Metabolic Disorders, 14 (1):
  • [10] Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus
    Tamez, Hector E.
    Tamez, Alejandra L.
    Garza, Lucas A.
    Hernandez, Mayra I.
    Polanco, Ana C.
    [J]. JOURNAL OF DIABETES AND METABOLIC DISORDERS, 2015, 14
12345